GB Sciences

What GB Sciences does

GB Sciences, Inc. (OTCQB: GBLX) is a Las Vegas-based, plant-inspired biopharmaceutical drug development company that operates its proprietary PhAROS™ AI-Powered Drug Discovery Platform to identify and predict the efficacy of combinations of novel active ingredients drawn from twelve global Traditional Medical Systems. The platform feeds a pipeline of five late-preclinical drug programs targeting Parkinson's disease (including the MEM.PD family of CCCM™ candidates with issued US Patent 10,653,640), chronic pain (MCCM™ myrcene-containing mixtures, US Patent 10,709,670, partnered with Catalent for Zydis ODT oral delivery), COVID-19-related cytokine release syndrome, heart failure, and stress/anxiety. Through its wholly-owned Canadian subsidiary GBS Global Biopharma, Inc. (Ottawa, formed March 2019), the company also develops nutraceutical and wellness licensing opportunities against its patent portfolio and pursues co-development arrangements with Purisys (cGMP cannabinoids), FHI Clinical (CRO), the National Research Council of Canada, and nine universities worldwide.

Revenue historically came from Nevada cannabis cultivation (Q1 2018 reported revenue of $1,315,284 with $734,719 gross profit), but the company sold 75% of the Las Vegas operation in 2024 for $8 million ($3 million cash plus a $3 million promissory note), eliminating approximately $5.77 million of annual operating expenses and completing a strategic pivot to a pre-commercial biopharmaceutical model. The current monetization model is licensing and royalty-based: GB Sciences has signed a deal with EndoPure Life Sciences providing a 5% gross sales royalty plus First-in-Human trial sponsorship for the Parkinson's program, and pursues patent licensing for nutraceutical and wellness channels. The company has no currently disclosed commercial product revenue and is reported as continuing to operate on the OTCQB at a GBLX share price of approximately $0.002.

Customer touchpoints today are largely scientific and corporate partners (Purisys, Catalent, FHI Clinical, EndoPure, nine international universities) and Historical Louisiana medical marijuana was distributed via nine licensed pharmacies (Metropolitan New Orleans through Madisonville) tied to the LSU AgCenter partnership. Leadership is led by CEO and Chairman John Poss, with Dr. Andrea Small-Howard as Chief Science Officer, Zach Swarts as CFO, and Michael Farley as President of the Canadian subsidiary; the company holds 8 US and 14 global issued patents (28 unique formulas) and 15 US and 41 global pending applications (25 unique formulas).

Name

GB Sciences

Legal name

Gb Sciences Inc.

Website

https://gbsciences.com

Company type

Public

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

GB Sciences is a Las Vegas-based plant-inspired biopharmaceutical company that uses its proprietary PhAROS™ AI Drug Discovery Platform to develop preclinical cannabinoid-based drug candidates for Parkinson's disease, chronic pain, cytokine syndromes, heart failure, and stress/anxiety, monetizing via licensing, royalties, and partnerships.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Drug Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medicinal and Botanical Manufacturing (325411), Research and Development in Nanotechnology (541713)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Plant-inspired drug discovery
• Cannabinoid therapeutics
• Biopharmaceutical development
• AI drug discovery
• Preclinical drug development

Headquarters

HQ city

Las Vegas

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Licensing and Partnerships: License proprietary drug formulations to larger pharmaceutical companies for clinical development and commercialization. Revenue generated through upfront payments, milestone payments, and royalties on sales. The company signed a licensing deal with EndoPure Life Sciences for 5% gross sales royalty and sponsorship of First-in-Human trial for their cannabinoid-based Parkinson’s drug.
2. Wellness and Nutraceutical Products: License formulations as nutraceuticals and natural health supplements for global licensing, enabling earlier monetization of patent portfolio before pharmaceutical development completion.
3. Cannabis Cultivation and Production (Former): Previously operated cannabis cultivation and production in Nevada. Sold 75% of Las Vegas operation for $6 million ($3M cash + $3M promissory note) to focus on biopharma. The sale eliminated $5.77 million of annual operating expenses.
4. Historical Cannabis Revenue: Q1 2018 reported revenue of $1,315,284 and gross profit of $734,719 from cannabis operations before pivot to biopharma focus.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

GB Sciences develops proprietary, AI-discovered plant-inspired drug formulations for licensing to pharmaceutical partners. Its PhAROS™ Drug Discovery Platform uses machine learning and high-throughput biology to identify Minimum Essential Mixtures from cannabinoids and terpenoids, delivered as Cannabinoid-Containing Complex Mixtures (CCCM™) and Myrcene-Containing Complex Mixtures (MCCM™). The pipeline includes five late-preclinical programs targeting Parkinson's disease, chronic pain, stress and anxiety, cytokine syndromes, and heart failure.

Product overview

GB Sciences is a biopharmaceutical drug development company that operates through its proprietary PhAROS™ AI-powered Drug Discovery Platform and multiple therapeutic programs. The platform generates proprietary formulations including Cannabinoid-Containing Complex Mixtures (CCCM™) and Myrcene-Containing Complex Mixtures (MCCM™) for specific disease applications. The company's pipeline includes five late preclinical programs targeting Parkinson's disease, chronic pain, stress & anxiety, cytokine syndromes, and heart failure. Their Canadian subsidiary GBS Global Biopharma manages international development. The company has 8 US and 14 global issued patents, with 15 US and 41 global patents pending.

Differentiator

Problem solved

Functional benefit

Products and services

• PhAROS™ Drug Discovery Platform
• Cannabinoid-Containing Complex Mixtures (CCCM™)
• Myrcene-Containing Complex Mixtures (MCCM™)
• Parkinson's Disease Therapeutics (MEM.PD119, MEM.PD205, MEM.PD361)
• Chronic Pain Therapeutics (GBS.CP110, GBS.CP121, GBS.CP139)
• COVID-19 Cytokine Release Syndrome Therapies

Quantifiable outcome

• Statistically significant reduction in Parkinson’s disease symptomology in animal proof-of-concept study (April 2020)
• +4 more outcomes

Named customers10 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

13 partnerships are on record, tiered core and minor.

• FHI ClinicalcoreStrategic or Co-development Partner · 2 May 2022Full-service contract research organization (CRO) selected as CRO to help with go-to-market strategy and draft clinical trial protocol for COVID-19 related anti-inflammatory therapeutics. Global expertise in managing complex clinical research.
• Catalent, Inc.coreTechnology or Integration · 26 September 2018Leading global provider of advanced delivery technologies and development solutions. Selected to provide oral delivery systems, formulation development, and clinical-scale oral dose manufacturing using proprietary Zydis ODT technology for Parkinson’s disease therapies. Proof of concept study at Swindon, UK facility.
• University of Athens, GreececoreStrategic or Co-development Partner · 19 September 2018Canna-bolomics Project: analyzes each of GB Sciences’ cultivars to determine whether additional molecules show promise to treat diseases. Full metabolomic studies using NMR & LC-MS techniques. Department ranks among top 100 Pharmacy Departments globally.
• Los Coyotes Band of Cahuilla & Cupeño IndiansminorStrategic or Co-development Partner · 1 January 2017Memorandum of understanding signed in 2017 to co-develop cultivation and manufacturing operations on tribal land in San Diego County. Part of collaboration with California Native American Cannabis Association (CNACA).
• LSU AgCenter (Louisiana State University Agricultural Center)coreStrategic or Co-development PartnerPublic-private partnership for Louisiana Medical Marijuana Program. LSU AgCenter conducted research and selected GB Sciences Louisiana as their exclusive private partner. GB Sciences operated a 36,000 sq ft cultivation and production facility in Baton Rouge, LA. Partnership underwent regulatory scrutiny but LSU AgCenter confirmed GB Sciences’ compliance with all LDAF requirements.
• National Research Council of Canada (NRC)coreStrategic or Co-development PartnerAnimal models used for establishing Proof-of-Concept for Optimized Therapeutic Mixtures for treatment of Parkinson’s disease and neuropathic pain. NRC’s Halifax lab uses zebrafish PD model that allows rapid validation and optimization of formulas. Demonstrated statistically significant reduction in Parkinson’s disease symptomology.
• Michigan State UniversitycoreStrategic or Co-development PartnerPreclinical models used for establishing Proof-of-Concept for Optimized Therapeutic Mixtures for treatment of Cytokine Release Syndrome in COVID-19 patients. Expertise in role of cannabinoids in inflammation. Cell-based models used in Drug Discovery Process.
• University of Cadiz, SpaincoreStrategic or Co-development PartnerAnimal Models used for establishing Proof-of-Concept for Optimized Therapeutic Mixtures in oral nanoparticles for treatment of neuropathic pain.
• University of HawaiicoreStrategic or Co-development PartnerAnimal Models used for establishing Proof-of-Concept for Optimized Therapeutic Mixtures for treatment of Heart Failure. Research on TRP channels in cardiovascular disease.
• The University of Lethbridge, CanadacoreStrategic or Co-development PartnerAnimal Models and “Home Cage Small World” assessments using cameras and Artificial Intelligence to assess efficacy of Optimized Therapeutic Mixtures for Parkinson’s disease.
• Purisys, LLCcoreTechnology or IntegrationGlobal leader in custom synthesis of active pharmaceutical ingredients and advanced intermediates. Supports pharma & biotech companies with APIs, reference standards, controlled substances, cannabinoids, and cGMP clinical & niche commercial CDMO services. Formed as spin-off from Noramco in 2019, manufacturing began in 1979 as part of Johnson & Johnson.
• Chaminade UniversitycoreStrategic or Co-development PartnerCell & Computer-based Models used in Drug Discovery Process; Ideation and creative contributions to IP portfolio. Dr. Helen Turner serves as VP Innovation and Scientific Advisory Board member. NIH RO1 grant recipient.
• University of Seville, SpaincoreStrategic or Co-development PartnerOral Nanoparticle Technology used to enhance drug delivery of Optimized Therapeutic Mixtures. Joint nanotech research program for time-release formulations.

Scale indicators11 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• Canopy Growth Corporation: Major cannabis company with biopharmaceutical partnerships (historically with Spectrum Therapeutics targeting cannabinoid-based medicines). Comparable as a cannabis industry peer that has similarly pursued pharmaceutical-grade cannabinoid development.
• Axsome Therapeutics: CNS-focused biopharmaceutical company with approved and pipeline therapies for neurological and psychiatric conditions. Comparable as a broader CNS pharmaceutical peer, though not cannabinoid-focused; represents competitive context for Parkinson's and pain indications.
• Tilray Brands: Large-scale cannabis company with biopharmaceutical division pursuing FDA-grade cannabinoid medicines. Comparable as a cannabis-to-pharma peer, though much larger and focused more on cultivation and consumer products alongside pharmaceutical aspirations.

Emerging players

• Anavex Life Sciences: Clinical-stage biopharmaceutical company developing treatments for Alzheimer's, Parkinson's, and other neurological diseases. Comparable as a small-cap CNS therapeutics developer targeting overlapping neurodegenerative indications.
• Mind Medicine (MindMed): Clinical-stage psychedelic medicine company developing CNS therapeutics based on plant-inspired compounds. Comparable as an emerging player pursuing novel plant-derived treatments for neurological and psychiatric conditions via FDA pathways.

Direct peers

• Zynerba Pharmaceuticals: Clinical-stage cannabinoid therapeutics company focused on transdermal CBD treatments for neurological and psychiatric conditions. Closely comparable in developing cannabinoid-based therapies for CNS indications using proprietary drug delivery approaches.
• Botanix Pharmaceuticals: Clinical-stage cannabinoid therapeutics company focused on dermatology and inflammatory conditions. Comparable in targeting specific indications with proprietary cannabinoid formulations and pursuing regulatory approval pathways.
• GW Pharmaceuticals: Pioneer in cannabinoid-based prescription medicines (developer of Epidiolex, the first FDA-approved CBD drug). Now part of Jazz Pharmaceuticals, it is the most direct historical peer in developing FDA-grade cannabinoid therapeutics targeting neurological conditions.
• InMed Pharmaceuticals: Clinical-stage company developing cannabinoid-based therapeutics using proprietary manufacturing and formulation approaches. Similar in combining proprietary IP-protected cannabinoid formulations with pharmaceutical development pathways.
• Corbus Pharmaceuticals: Develops cannabinoid-derived and related small molecule therapeutics for inflammatory and fibrotic diseases. Comparable in business model of advancing novel cannabinoid-inspired drug candidates through clinical development toward licensing deals.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/gbsciencesinc
• YouTubeyoutube.com/channel/UC2oqEu2Ugrk8udtJaLIeupg
• Facebookfacebook.com/427189244079726
• LinkedInlinkedin.com/company/gbsciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GB Sciences